佛慈制药
(002644)
| 流通市值：43.97亿 | | | 总市值：43.97亿 |
| 流通股本：5.11亿 | | | 总股本：5.11亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 429,365,466.8 | 216,124,672.92 | 980,225,387.73 | 708,531,496.45 |
| 营业收入 | 429,365,466.8 | 216,124,672.92 | 980,225,387.73 | 708,531,496.45 |
| 二、营业总成本 | 380,743,426.65 | 189,743,028.4 | 903,743,257.88 | 651,587,799.98 |
| 营业成本 | 283,945,418.43 | 142,041,673.69 | 680,513,278.37 | 481,626,455.52 |
| 税金及附加 | 7,297,901.64 | 3,945,047.38 | 14,095,061.43 | 9,996,270.2 |
| 销售费用 | 46,903,224.22 | 20,231,809.02 | 116,044,604.78 | 93,057,848.76 |
| 管理费用 | 31,729,859.9 | 16,347,923.44 | 68,957,995.3 | 49,498,710.96 |
| 研发费用 | 13,281,225.46 | 7,741,713.66 | 29,284,084.57 | 21,768,633.09 |
| 财务费用 | -2,414,203 | -565,138.79 | -5,151,766.57 | -4,360,118.55 |
| 其中:利息费用 | 378,448.66 | - | 831,438.63 | 973,583.61 |
| 其中:利息收入 | 2,831,725.28 | - | 5,743,444.14 | 5,445,098.27 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -3,921,948.13 | -1,015,474.66 | -7,233,165.17 | -6,521,859.04 |
| 资产处置收益 | 1,415.92 | 1,415.92 | 40,438.07 | 11,680.13 |
| 资产减值损失(新) | - | - | -151,744.5 | -17,690.4 |
| 信用减值损失(新) | -21,479,697.36 | -8,024,525.12 | -33,666,912.41 | -21,135,076.43 |
| 其他收益 | 11,384,545.76 | 5,568,578.12 | 34,974,982.54 | 17,037,926.07 |
| 四、营业利润 | 34,606,356.34 | 22,911,638.78 | 70,445,728.38 | 46,318,676.8 |
| 加:营业外收入 | 1,322,171.77 | 894,830.1 | 435,595.54 | 32,958.97 |
| 减:营业外支出 | 1,289,781.43 | 73,627.47 | 1,741,820.55 | 679,810.7 |
| 五、利润总额 | 34,638,746.68 | 23,732,841.41 | 69,139,503.37 | 45,671,825.07 |
| 减:所得税费用 | 4,692,312.26 | 3,608,602.78 | 7,473,892.6 | 5,223,143.28 |
| 六、净利润 | 29,946,434.42 | 20,124,238.63 | 61,665,610.77 | 40,448,681.79 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 29,946,434.42 | 20,124,238.63 | 61,665,610.77 | 40,448,681.79 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 30,104,611.31 | 19,381,644.03 | 60,069,813.05 | 39,072,938.02 |
| 少数股东损益 | -158,176.89 | 742,594.6 | 1,595,797.72 | 1,375,743.77 |
| 扣除非经常损益后的净利润 | 20,850,937.98 | 14,350,387.51 | 32,406,746.33 | 25,181,166.19 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.04 | 0.12 | 0.08 |
| (二)稀释每股收益 | 0.06 | 0.04 | 0.12 | 0.08 |
| 八、其他综合收益 | 43,576.26 | - | 130,949.54 | 487,793.63 |
| 归属于母公司股东的其他综合收益 | 22,469.01 | - | 68,427.66 | 251,518.59 |
| 九、综合收益总额 | 29,990,010.68 | 20,124,238.63 | 61,796,560.31 | 40,936,475.42 |
| 归属于母公司股东的综合收益总额 | 30,127,080.32 | 19,381,644.03 | 60,138,240.71 | 39,324,456.61 |
| 归属于少数股东的综合收益总额 | -137,069.64 | 742,594.6 | 1,658,319.6 | 1,612,018.81 |
| 公告日期 | 2025-08-27 | 2025-04-26 | 2025-04-26 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |